The Oral Solid Dosage Contract Manufacturing Market Worth $54.7 Billion by 2030: Grand View Research, Inc.

SAN FRANCISCO, July 6, 2022 /PRNewswire/ — The global oral solid dosage contract manufacturing market size is expected to reach $54.7 billion by 2030, recording a CAGR of 6.0% over the forecast period, according to a new report from Grand View Research, Inc. Increasing complexity of new drug molecules, R&D investments by large contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) and growing demand for new therapies would drive the growth of the market. Oral solids are the most widely accepted dosage forms in the pharmaceutical industry because they are economical, simple to manufacture, and patient friendly. Additionally, advances in drug delivery technology, such as drug delivery and sustained release training, allow oral solids to achieve even higher levels of bioavailability while reducing the frequency of administration. medication.

Grand View Search Logo

Key industry insights and findings from the report:

  • The tablet segment dominated the market in 2021. Tablets are the most common OSD forms. It is the most popular dosage due to its compactness, easy manufacture, and convenience of self-administration.

  • Increased demand for bilayer tablets and corporate investments to develop the formulation and manufacturing of controlled release tablets are driving the growth of the market.

  • On an end-user basis, the large enterprise segment accounted for the largest revenue share in 2021. The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and a high level of adaptability.

  • As more pharma developers design drugs from the ground up with the intention of outsourcing them to large CMOs, it’s only natural that large CMOs have more clout in the development pipeline.

  • Asia Pacific dominated the global market in 2021 and is expected to witness the fastest CAGR over the forecast years, as China and India are OSD CMO engines with significantly lower prices.

Read the 275-page Market Research Report for more insights, “Oral Solid Dosage Contract Manufacturing Market Size, Share and Trends Analysis Report by Product Type ( tablets, capsules), by mechanism (controlled release, immediate release), by end-user, by region and segment forecast, 2022 – 2030”, published by Grand View Research.

Oral Solid Dosage Contract Manufacturing Market Growth and Trends

The global market is growing alongside the oncology sector. Clinical-stage cancer programs have increased by 77% between 2015 and 2020 (1,642 to 2,911) and completely dominate the landscape, resulting in around a quarter of drugs currently being developed worldwide being classified as very powerful. This trend towards high power is having a significant impact on the CDMO space, as the growing demand for smaller scale and encapsulated manufacturing processes presents a challenge for most of the pharmaceutical industry’s installed capacities. The COVID-19 crisis has had a number of short and long term consequences.

The healthcare industry has seen a significant decline in revenue recognition in the year 2020 due to labor shortages and disruption in the raw material supply chain. However, drug developers are focused on improving their efforts in the R&D of pharmaceuticals that will help treat viral infections. Additionally, small molecule oral solid dosage (OSD) products, such as azithromycin and hydroxychloroquine, etc. have a positive impact on the population infected with COVID-19. Hence, an increasing number of manufacturers have focused on the marketing and production of these OSD drugs, thereby supporting the growth of the market.

Additionally, the industry has witnessed a significant increase in 2020 and 2021 as a new and high number of CMOs have been awarded OSD contracts as a potential treatment for COVID-19 infection. For example, in August 2020, Pfizer Inc. announced an agreement with Gilead Sciences, Inc. to provide contract manufacturing services for the supply and manufacture of Gilead’s investigational antiviral drug remdesivir, with the goal of increasing supply of the investigational treatment for COVID-19 patients. Hence, these factors support the surge in demand for OSD products in 2020 and 2021.

Oral Solid Dosage Contract Manufacturing Market Segmentation

Grand View Research has segmented the global solid oral dosage contract manufacturing market on the basis of product type, mechanism, end-user, and region:

OSD Contract Manufacturing Market – Product Type Outlook (Revenue, USD Million, 2018 – 2030)

  • Tablets

  • capsules

  • Powders

  • pellets

  • Others (Lozenges, Gummies, Lozenges, etc.)

OSD Contract Manufacturing Market – Mechanism Outlook (Revenue, USD Million, 2018 – 2030)

  • Immediate launch

  • Delayed broadcast

  • Controlled release

OSD Contract Manufacturing Market – End User Outlook (Revenue, USD Million, 2018 – 2030)

OSD Contract Manufacturing Market – Regional Outlook (Revenue, USD Million, 2018 – 2030)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

List of Key Players of Oral Solid Dosage (OSD) Contract Manufacturing Market

Check out other related studies published by Grand View Research:

  • Healthcare Contract Manufacturing MarketThe size of the global healthcare contract manufacturing market is expected to reach $512.7 billion by 2030, growing at a CAGR of 9.6% over the forecast period, according to a new report from Grand View Research, Inc. forecast period. Many businesses have experienced lost sales and operating profits during the COVID-19 pandemic. According to Jabil, Inc., COVID-19 has increased expenses, primarily related to additional labor costs and the purchase of PPE for employees globally, and has resulted in reduced use of factories due to disruptions and travel restrictions.

  • Contract Manufacturing of Biopharmaceuticals Market – The global contract manufacturing of biopharmaceuticals market size is expected to reach $27.3 billion by 2030, growing at a CAGR of 5.2% from 2022 to 2030, according to a new report from Grand View Research, Inc. Growth in the biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors driving stimulate partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contractors are committed to expanding their service portfolio to meet business demands for regulatory standards and new services. The pandemic has, however, also had negative ripple effects, as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.

  • Biologics Contract Manufacturing Market – The global biologics contract manufacturing market size is expected to reach $34.7 billion by 2030, registering a CAGR of 10.5% over the forecast period, according to a new report by Grand View Research, Inc. The global market has been growing efficiently during the COVID-19 pandemic. This is due to an increase in R&D activities for the development of COVID-19 vaccines. Additionally, there has been an expansion of manufacturing facilities to control the spread of the disease. For example, in November 2021Lonza has announced that it has decided to expand its microbial development laboratories to Swiss to support the company’s future projects.

Browse Grand View Research results Medical device industry Research reports.

About Grand View Research

Grand View Research, a US-based market research and consulting firm, provides syndicated and custom research reports and consulting services. Checked in California and whose head office is at San Francisco, the company has more than 425 analysts and consultants, adding more than 1,200 market research reports to its extensive database each year. These reports offer in-depth analysis of 46 industries in 25 major countries around the world. Using an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and assess upcoming opportunities.

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Grand View Compass | Astra ESG Solutions
Follow us: LinkedIn | Twitter




View original content: – 301581317.html

SOURCEGrand View Research, Inc.

Comments are closed.